Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 16/20 | 0.72 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.58 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867212 | 0.88 | RYR2 (0.78) | RYR2NOTUMKCNH2 | |
| SCHEMBL6867029 | 0.84 | RYR2 (1.00) | RYR2NOTUMKCNH2 | |
| SCHEMBL9635059 | 0.84 | RYR2 (0.72) | RYR2NOTUMKCNH2 | |
| SCHEMBL6866477 | 0.84 | RYR2 (0.72) | RYR2NOTUMKCNH2 | |
| SCHEMBL7555363 | 0.83 | RYR2 (0.69) | RYR2NOTUMKCNH2 | |
| SCHEMBL6868429 | 0.83 | RYR2 (0.76) | RYR2NOTUMKCNH2 | |
| SCHEMBL13622149 | 0.83 | RYR2 (0.71) | RYR2KCNH2 | |
| SCHEMBL13622119 | 0.82 | RYR2 (0.54) | RYR2 | |
| SCHEMBL13622102 | 0.81 | RYR2 (0.78) | RYR2NOTUMKCNH2 | |
| SCHEMBL806938 | 0.81 | RYR2 (1.00) | RYR2NOTUMKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0667866-B1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | KNOLL AG (DE) | 1998-03-11 | — | — | EP | claimed |
| US-5580866-A | Therapeutic 1,4-thiazepines | THE BOOTS COMPANY PLC (GB) | 1996-12-03 | — | — | US | claimed |
| EP-0667866-A1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | Knoll AG (DE) | 1995-08-23 | — | — | EP | claimed |
| WO-1994011360-A1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | THE BOOTS COMPANY PLC (GB) | 1994-05-26 | — | — | WO | claimed |
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYCARMA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230302013-A1 | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-09-28 | — | — | US | disclosed |
| CN-109879837-B | Methods of preparing compounds for preventing and treating RSV | 上海爱科百发生物医药技术股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3248969-B1 | PROCESS FOR THE PREPARATION OF N-[3-(AMINOMETHYL)OXETAN-3-YL]CARBAMATE INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3097098-B1 | PROCESS FOR THE PREPARATION OF N-[(3-AMINOOXETAN-3-YL)METHYL]-2-(1,1-DIOXO-3,5-DIHYDRO-1,4-BENZOTHIAZEPIN-4-YL)-6-METHYL-QUINAZOLIN-4-AMINE | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3097098-B1 | PROCESS FOR THE PREPARATION OF N-[(3-AMINOOXETAN-3-YL)METHYL]-2-(1,1-DIOXO-3,5-DIHYDRO-1,4-BENZOTHIAZEPIN-4-YL)-6-METHYL-QUINAZOLIN-4-AMINE | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| WO-2001000185-A2 | 1,4-DENZOTHIAZEPINES TO TREAT OBESITY RELATED DISORDERS | KNOLL GMBH (DE) | 2001-01-04 | — | — | WO | disclosed |
| EP-0667866-B1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | KNOLL AG (DE) | 1998-03-11 | — | — | EP | disclosed |
| US-5580866-A | Therapeutic 1,4-thiazepines | THE BOOTS COMPANY PLC (GB) | 1996-12-03 | — | — | US | disclosed |
| EP-0667866-A1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | Knoll AG (DE) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994011360-A1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | THE BOOTS COMPANY PLC (GB) | 1994-05-26 | — | — | WO | disclosed |
| EP-0368063-B1 | PROCESS FOR THE CHLORINATION IN THE NUCLEUS OF AROMATIC HYDROCARBONS | BAYER AG (DE) | 1992-06-10 | — | — | EP | disclosed |
| US-4990707-A | Process for the ring chlorination of aromatic hydrocarbons | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-05 | — | — | US | disclosed |
| EP-0368063-A1 | Process for the chlorination in the nucleus of aromatic hydrocarbons | BAYER AG (DE) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302013-A1 | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS | RYR2, RYR1, CACNB1 | RYR2 1/4885NOTUM 3049/4885HSD17B3 2012/4885 |
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYR2, RYR1, ATP2A1 | RYR2 1/4885NOTUM 3503/4885HSD17B3 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.